It began July 1, 2026, and allows eligible Part D beneficiaries to get access to weight-loss GLP-1s for a flat $50 a month
Despite the high prevalence of lipedema, which affects 10% of women, and its significant impact on patient quality of life, lipedema is understudied and often misdiagnosed as other disorders (obesity or lymphedema)
findings are preclinical only, not approved
"Until broader access, durable adherence and sustained population-level outcomes are demonstrated, cheaper airfare should be viewed as a theoretical possibility not a predictable consequence of weight-loss drug use." CLICK HERE FOR MORE HEALTH STORIES Dr
Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1
These drugs require dose titration, particularly to reduce adverse effects like nausea and diarrhea that are common soon after starting therapy, Dr